A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)

Phase I/II Clinical Study of Armored and GPC3-targeted Autologous Chimeric Antigen Receptor (CAR) T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

This single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/recurrent HCC, who have progressed or are intolerant to at least two prior lines of standardized systemic therapy, and lack of other effective treatments.

Study Overview

• Status: Recruiting
• Conditions: Hepatocellular Carcinoma
• Intervention / Treatment: Biological: Armored and GPC3-targeted autologous CAR T-cell

Detailed Description

Part A (Phase I) is divided into two sections: dose escalation (Part A1) and dose expansion (Part A2). Part A1 will determine the recommended dose for expansion (RDE) to be used in Part A2 (dose expansion) of the study. Part A2 will further evaluate the safety, tolerability and efficacy of C-CAR031 to determine the recommended phase II dose (RP2D) to be used in Part B (Phase II).

• Study Type: Interventional
• Enrollment (Estimated): 121
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Andy Zou; Phone Number: +86-21-54069990; Email: Andy.Zou@abelzeta.com
• Study Contact Backup: Name: Nicole Shen; Phone Number: +86-21-54069993; Email: yinghua.shen@abelzeta.com

Study Locations

• China
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200032
      • Recruiting
      • Zhongshan Hospital Fudan University
      • Contact: Jia Fan, Dean; Phone Number: 86-21-64041990; Email: fan.jia@zs-hospital.sh.cn
  • Zhejiang
    • Hanzhou, Zhejiang, China, 310003
      • Recruiting
      • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Contact: Tingbo Liang, Dean; Phone Number: +8613666676128; Email: liangtingbo@zju.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. The participant voluntarily participates in the study, and the individual or their legal guardian signs the informed consent form (ICF).
2. 18 ~ 75 years of age at the time of signing ICF.

3. Clinical trial participants with advanced HCC confirmed by histopathological or cytological examination with the following requirements (no mixed HCC-cholangiocarcinoma permitted):

   • Barcelona Clinic Liver Cancer (BCLC) stage C or B (not amenable to surgery/local treatment, includes ablative therapy, interventional and radiation therapy) or stage II-III ( not amenable to surgery/local treatment, includes ablative therapy, interventional and radiation therapy) per China liver cancer staging (CNLC).
   • Child-Pugh score ≤ 6.
   • Participants must have a GPC3-positive tumor as determined by a central laboratory using an analytically validated IHC assay. Participants with unknown GPC3 status are not eligible for this study.
4. Participants who have progressed or are intolerant to at least two prior lines of standardized systemic therapy, and lack of other effective treatments; Systemic therapy intolerance is defined as: drug-related adverse reactions or side effects caused by systemic therapy (including but not limited to targeted therapy, immunotherapy) in patients with HCC that prevent patients from continuing treatment.
5. At least one measurable target lesion (as defined by RECIST v1.1) that has not undergone prior local therapies such as radiotherapy (excluding lesions with radiologically confirmed progression after local therapy), and has not been utilized for research pre-screening biopsies (if only one target lesion exists and must undergo tissue biopsy, baseline tumor imaging must be performed at least 14 days after the biopsy).
6. ECOG performance status score of 0 or 1.
7. Minimal life expectancy ≥12 weeks, per the Investigator's discretion.
8. The left ventricular ejection fraction (LVEF) measured by echocardiography ≥45% and reported as non-impaired. Measure must be within 28 days prior to apheresis.

9. The laboratory testing results meet the following study requirements. Blood routine examination

   • *Absolute Neutrophil Count (ANC) ≥1.0×10^9/L.
   • Absolute Lymphocyte count ≥ 0.3×10^9/L.
   • *Platelet count ≥ 75×10^9/L.
   • Hemoglobin ≥ 80g/L. * With no transfusion or blood component transfusion received within 28 days prior to blood sampling or within 14 days prior to apheresis; or, with no granulocyte colony-stimulating factor (G-CSF) or other hematopoietic stimulators administered as supportive treatment within 28 days prior to blood sampling or within 21 days prior to apheresis.

   Blood biochemistry

   • Serum total bilirubin ≤ 2.5×ULN (upper limit of normal) in the absence of Gilbert's syndrome, or ≤ 3×ULN if the patient has Gilbert's syndrome.
   • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤5×ULN.
   • Albumin ≥ 2.8 g/dL.
   • *Calculated creatinine clearance ≥30ml/min. ＊As determined by Cockcroft-Gault equation using actual body weight.

   Coagulation

   • Prothrombin time International normalized ratio (PT-INR) ≤1.6.

10. Participants with Hepatitis B virus (HBV) infection or history of infection (as characterized by positive HBsAg, [hepatitis B surface antigen], and/or detectable HBV DNA, and/or HbcAb [hepatitis B core antibody]) are eligible for inclusion only if:

    • The participant is treated with antiviral therapy, as per institutional practice, to ensure adequate viral suppression (HBV DNA less than 2,000 IU/mL or 10,000 copies/mL).
    • Participants who test positive for HBsAg and/or HBcAb must initiate standard antiviral therapy according to the most recent edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B at least 1 week prior to cell infusion, with tenofovir recommended as the preferred antiviral agent.
11. Female participants of childbearing potential must test negative for pregnancy in serum or urine; non-sterilized participants (males and females) agree to take effective contraceptive measures for at least 12 months or CAR-T below lower limit of detection (LLD) by droplet digital polymerase chain reaction (ddPCR) whichever occurs first after C-CAR031 infusion (including participants who have only received lymphodepleting chemotherapy).

Exclusion Criteria:

1. Known life-threatening allergies, hypersensitivity, or intolerance to the CAR-T product or its excipients, including dimethyl sulfoxide (DMSO).
2. Known allergies to lymphodepleting agents, including fludarabine and/or cyclophosphamide.
3. History of hepatic encephalopathy within past 6 months prior to apheresis or requirement for medications to prevent or control encephalopathy (eg, lactulose, rifaximin, etc infused for purposes of hepatic encephalopathy).
4. Participants with central nerve system (CNS) diseases such as epilepsy, severe cerebral vascular stenosis, or those who have had a cerebral infarction or other cerebral vascular accidents within 6 months, or other diseases with obvious neurological symptoms (including mental illnesses).
5. Uncontrolled or intercurrent cardiac or pulmonary diseases, including but not limited to, chronic obstructive pulmonary disease with obvious symptoms, and moderate or above persistent asthma, with a known history of non-infectious pneumonia requiring steroid treatment, or those presenting with acute exacerbation or progressive non-infectious pneumonia at baseline, unstable angina, severe arrhythmia, severe non-ischemic cardiomyopathy history or myocardial infarction or cardiac vascular surgery treatment occurred within 6 months.
6. History of organ transplant including liver.

7. Prior treatment with:

   • Any CAR-T therapy. OR
   • Any therapy that is targeting GPC3.
8. The tumor volume is larger than 50% of the liver tissue.
9. Main portal vein cancer embolus (Vp4, cancer embolus in the main trunk of the portal vein, with or without blood flow) on pre-LDC imaging.
10. History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to apheresis.
11. Clinically meaningful ascites, defined as any ascites requiring non-pharmacologic intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior to apheresis. Participants on stable doses of diuretics for ascites for ≥ 2 months prior to apheresis are eligible.
12. Uncontrolled pleural effusion or pericardial effusion requiring recurrent drainage procedures (once monthly or more frequently).
13. Cancer-related spinal cord compression, leptomeningeal disease, or brain metastases unless asymptomatic, treated, and stable radiologically (defined as 2 brain images, [both after treatment], should both be obtained at least 4 weeks apart and show no evidence of intracranial progression) and resolved or stable clinically; not requiring continuous corticosteroids at a dose above10 mg/day prednisone or equivalent for at least 4 weeks prior to apheresis.
14. Received radiation therapy within 6 weeks of apheresis, or received local radioactive particle implantation within 6 months or 3 half-lives (whichever is longer).
15. Received local treatment (such as: surgery, ablation, transarterial-chemoembolization [TACE]) within 4 weeks of apheresis, or existence of unhealed wound.
16. Received inactivated or live attenuated vaccine within 4 weeks prior to apheresis.
17. Blood transfusions within 14 days and/or growth factor support within 21 days prior to apheresis.

18. Received systemic treatment and did not meet the minimum requirement for washout before apheresis:

    • Immune checkpoint inhibitor: within 5 half-lives or 2 weeks (whichever is shorter).
    • Chemotherapy, small molecule targeted therapy: within 5 half-lives or 2 weeks (whichever is shorter).
    • Experimental anticancer drugs or other anti-cancer systemic treatment including Chinese herbal medicine, Chinese patent drug: within 5 half-lives or 2 weeks (whichever is shorter).
    • Systemic dosing of steroid(s) (excluding: intranasal, inhaled, topical steroids or local steroid injections [eg, intra-articular injection]; systemic corticosteroids at physiologic doses not exceed 10mg/day of prednisone or its equivalent; steroids as premedication for hypersensitivity reaction [eg, computed tomography [CT] scan premedication]) or other immunomodulators (eg. Interleukins, interferons, thymosins, etc.): within 5 half-lives or 2 weeks (whichever is shorter).

19. Has a history of other primary cancers, with exceptions of:

    • Tumors with low metastatic potential that have been cured by excision (such as: basal cell carcinoma of the skin).
    • Cured carcinoma in situ.
20. History of or with active immunodeficiency diseases (including but not limited to HIV [Human immunodeficiency virus; positive HIV 1/2 antibodies], systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, myasthenia gravis, Graves disease, pituitary inflammation, multiple sclerosis, neuromyelitis optica spectrum disorders, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyradiculoneuropathy, etc.; The following are exceptions: participants with vitiligo or alopecia, participants with hypothyroidism who have stabilized after hormone replacement therapy, any chronic skin disease that does not require systemic treatment, and other diseases that deemed not clinically significant per the Investigator's discretion).
21. Active Hepatitis C virus infection (Hepatitis C virus [HCV] antibody positive and HCV RNA positive).
22. According to the medical history, the participants who were known to have co-infection with HBV and hepatitis D virus (HDV).
23. Syphilis infection (Syphilis antigen and antibody positive).
24. Active infection requires systemic treatment (prophylactic administration of anti-infection medication is permitted; those who initiated antiviral therapy for HBV infection before screening must continue treatment throughout the study; for HBsAg-positive and/or HBcAb-positive participants not on antivirals before screening, antiviral therapy must be initiated at least 1 week prior to cell infusion, with tenofovir preferred as the antiviral agent).
25. History of cardiac arrhythmia (such as multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v5.0 Grade 3); unless controlled by pacemaker (discussion with the Study Physician required); symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
26. Clear clinical evidence of dementia or changes in mental state.
27. Heart failure: heart function of Class III or IV per the New York Heart Association (NYHA) heart function classification standards.
28. Participants use full-dose long acting oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose. Use of short acting direct oral anticoagulants for therapeutic and prophylactic purposes are permitted.
29. Participants with any of the following hemorrhage-related conditions: Active bleeding events ≥ Grade 3 (per NCI CTCAE v5.0) within 12 months prior to apheresis, Documented history of gastrointestinal variceal bleeding, or clinically significant history of upper gastrointestinal hemorrhage.
30. Obvious risk or tendency of bleeding.
31. Being in pregnancy or lactation period, or having plan to conceive during the study period.
32. History or current evidence of any condition, therapy, or laboratory abnormality that, per the Investigator's discretion, might confound the results of the study, interfere with the participant's safety and/or study compliance.
33. Major surgery within 2 weeks prior to apheresis, or has surgery planned during the study, or within a minimum of 4 weeks after study treatment administration. (Note: participants with planned surgical procedures to be conducted under local anaesthesia may participate).
34. Any unresolved toxicity NCI CTCAE ≥ Grade 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values. Participants with irreversible toxicity not reasonably expected to be exacerbated by treatment with study intervention including Grade 2 neuropathy maybe included after consultation with the Sponsor.
35. Patients with alcohol or drug abuse.
36. Participants with HLTV infection (HLTV antibody positive).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: C-CAR031; Dose escalation section (Part A1) utilizes a '3+3' design to explore the recommended dose for expansion (RDE). Initially, two dose levels (DLs) will be assessed. Patients in the dose escalation section will receive autologous C-CAR031 via intravenous (IV) infusion at DL1 and DL2.; Dose expansion (Part A2) will evaluate the safety and tolerability of C-CAR031 to determine RP2D to be used in Part B (Phase II). Patients in the dose expansion section will receive autologous C-CAR031 via IV infusion at the RDE.; The patients in the Phase II section (Part B) will receive autologous C-CAR031 via IV infusion at the RP2D, which will be determined after Part A by SRC.

Biological: Armored and GPC3-targeted autologous CAR T-cell; Armored and GPC3-targeted autologous CAR T-cells, single infusion intravenously.; Other Names: C-CAR031

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase I: Safety and tolerability	• Incidence, correlation and severity of adverse events (AEs).	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Safety and tolerability	• Incidence, correlation and severity of serious adverse events (SAEs)	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Safety and tolerability	• Incidence, correlation and severity of adverse events of special interest (AESIs)	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Safety and tolerability	• Incidence and severity of dose limiting toxicities (DLTs)	Throughout the 28 days post C-CAR031 infusion.
Phase I: Safety and tolerability	• Changes from baseline in vital signs (including temperature, systolic and diastolic blood pressure, pulse, respiratory rate, blood oxygen saturation) that are abnormal and of clinically significance.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Safety and tolerability	• Changes from baseline in physical examination (including the general appearance, respiratory, cardiovascular, abdomen, skin, head and neck, lymph nodes, thyroid, musculoskeletal, and neurological systems) that are abnormal and of clinically significance.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Safety and tolerability	• Changes from baseline in Eastern Cooperative Oncology Group (ECOG) score that are abnormal and of clinically significance (ECOG performance status score above 1).	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Safety and tolerability	• Changes from baseline in 12-lead electrocardiograms (ECGs) that are abnormal and of clinically significance.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Safety and tolerability	• Changes from baseline in laboratory test results (including the clinical chemistry, haematology, coagulation, urinalysis, serology, pregnancy assessments) that are abnormal and of clinically significance.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• Objective response rate (ORR) assessed by independent review committee (IRC) and evaluated according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase I: Pharmacokinetics	• Quantification of CAR transgene DNA copies of C-CAR031 in peripheral blood.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Pharmacokinetics	• Time to reach maximum concentration (Tmax) of C-CAR031 in peripheral blood	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Pharmacokinetics	• Maximum observed concentration (Cmax) of C-CAR031 in peripheral blood	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Pharmacokinetics	• Area under the curve 28 days after C-CAR031 infusion(AUC0-28d)	Throughout the 28 days post C-CAR031 infusion.
Phase I: Pharmacokinetics	• Last measurable concentration (Clast)	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Pharmacokinetics	• Time of Clast (Tlast)	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Pharmacokinetics	• Area under the curve from time 0 to the time of the last quantifiable concentration (AUClast)	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Anti-tumor activity	• ORR assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Anti-tumor activity	• Disease control rate (DCR) assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Anti-tumor activity	• Duration of response (DoR) assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Anti-tumor activity	• Durable response rate (DRR) assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Anti-tumor activity	• Time to response (TTR) assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Anti-tumor activity	• Progression-free survival (PFS) assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Anti-tumor activity	• Change in tumor size assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase I: Anti-tumor activity	• Overall survival (OS)	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• OS	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• ORR assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• DCR assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• DoR assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• DRR assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• TTR assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• PFS assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• Change in tumor size assessed by the Investigator and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• DCR assessed by the IRC and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• DoR assessed by the IRC and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• DRR assessed by the IRC and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• TTR assessed by the IRC and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• PFS assessed by the IRC and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Anti-tumor activity	• Change in tumor size assessed by the IRC and evaluated according to RECIST 1.1 criteria	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Safety and tolerability	• Incidence, correlation and severity of AEs.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Safety and tolerability	Incidence, correlation and severity of SAEs.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Safety and tolerability	• Incidence, correlation and severity of AESIs.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Safety and tolerability	• Changes from baseline in vital signs (including temperature, systolic and diastolic blood pressure, pulse, respiratory rate, blood oxygen saturation) that are abnormal and of clinically significance.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Safety and tolerability	• Changes from baseline in physical examination (including the general appearance, respiratory, cardiovascular, abdomen, skin, head and neck, lymph nodes, thyroid, musculoskeletal, and neurological systems) that are abnormal and of clinically significance.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Safety and tolerability	• Changes from baseline in Eastern Cooperative Oncology Group (ECOG) score that are abnormal and of clinically significance (ECOG performance status score above 1).	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Safety and tolerability	• Changes from baseline in 12-lead electrocardiograms (ECGs) that are abnormal and of clinically significance.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Safety and tolerability	• Changes from baseline in laboratory test results that are abnormal and of clinically significance.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Pharmacokinetics	• Quantification of CAR transgene DNA copies of C-CAR031 in peripheral blood.	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Pharmacokinetics	• Tmax of C-CAR031 in peripheral blood	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Pharmacokinetics	• Cmax of C-CAR031 in peripheral blood	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Pharmacokinetics	• AUC0-28d of C-CAR031 in peripheral blood	Throughout the 28 days post C-CAR031 infusion.
Phase II: Pharmacokinetics	• Tlast of C-CAR031 in peripheral blood	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Pharmacokinetics	• Clast of C-CAR031 in peripheral blood	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.
Phase II: Pharmacokinetics	• AUClast of C-CAR031 in peripheral blood	Throughout the study period, which extends up to 24 months after the administration of C-CAR031.

Collaborators and Investigators

• Sponsor: Shanghai AbelZeta Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2024
• Primary Completion (Estimated): April 30, 2030
• Study Completion (Estimated): April 30, 2043

Study Registration Dates

• First Submitted: September 1, 2024
• First Submitted That Met QC Criteria: September 5, 2024
• First Posted (Actual): September 19, 2024

Study Record Updates

• Last Update Posted (Estimated): January 2, 2026
• Last Update Submitted That Met QC Criteria: December 28, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Digestive System Neoplasms; Digestive System Diseases; Liver Diseases; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: 0921-041

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No